MDT Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 15.42% compared to Medtronic Plc's net margin of 14.91%. Medtronic Plc's return on equity of 9.84% beat Boston Scientific Corp.'s return on equity of 12.46%.

Medtronic Plc has a consensus price target of $110.32, signalling upside risk potential of 8.18%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 29.43%. Given that Boston Scientific Corp. has higher upside potential than Medtronic Plc, analysts believe Boston Scientific Corp. is more attractive than Medtronic Plc.

Medtronic Plc has a beta of 0.710, which suggesting that the stock is 28.968% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Medtronic Plc has a quarterly dividend of $0.71 per share corresponding to a yield of 2.77%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic Plc pays 77.47% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Medtronic Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic Plc quarterly revenues are $9B, which are larger than Boston Scientific Corp. quarterly revenues of $5.1B. Medtronic Plc's net income of $1.4B is higher than Boston Scientific Corp.'s net income of $755M. Notably, Medtronic Plc's price-to-earnings ratio is 27.55x while Boston Scientific Corp.'s PE ratio is 52.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic Plc is 3.78x versus 7.54x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.42% compared to Medtronic Plc's net margin of 28.31%. Medtronic Plc's return on equity of 9.84% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Medtronic Plc has a consensus price target of $110.32, signalling upside risk potential of 8.18%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $592.96 which suggests that it could grow by 4.08%. Given that Medtronic Plc has higher upside potential than Intuitive Surgical, Inc., analysts believe Medtronic Plc is more attractive than Intuitive Surgical, Inc..

Medtronic Plc has a beta of 0.710, which suggesting that the stock is 28.968% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

Medtronic Plc has a quarterly dividend of $0.71 per share corresponding to a yield of 2.77%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic Plc pays 77.47% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Medtronic Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic Plc quarterly revenues are $9B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Medtronic Plc's net income of $1.4B is higher than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Medtronic Plc's price-to-earnings ratio is 27.55x while Intuitive Surgical, Inc.'s PE ratio is 75.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic Plc is 3.78x versus 21.55x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 15.42% compared to Medtronic Plc's net margin of 21.47%. Medtronic Plc's return on equity of 9.84% beat Johnson & Johnson's return on equity of 33.27%.

Medtronic Plc has a consensus price target of $110.32, signalling upside risk potential of 8.18%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Medtronic Plc has higher upside potential than Johnson & Johnson, analysts believe Medtronic Plc is more attractive than Johnson & Johnson.

Medtronic Plc has a beta of 0.710, which suggesting that the stock is 28.968% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Medtronic Plc has a quarterly dividend of $0.71 per share corresponding to a yield of 2.77%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Medtronic Plc pays 77.47% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic Plc quarterly revenues are $9B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Medtronic Plc's net income of $1.4B is lower than Johnson & Johnson's net income of $5.2B. Notably, Medtronic Plc's price-to-earnings ratio is 27.55x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic Plc is 3.78x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.42% compared to Medtronic Plc's net margin of 14.18%. Medtronic Plc's return on equity of 9.84% beat Stryker Corp.'s return on equity of 14.06%.

Medtronic Plc has a consensus price target of $110.32, signalling upside risk potential of 8.18%. On the other hand Stryker Corp. has an analysts' consensus of $428.96 which suggests that it could grow by 17.22%. Given that Stryker Corp. has higher upside potential than Medtronic Plc, analysts believe Stryker Corp. is more attractive than Medtronic Plc.

Medtronic Plc has a beta of 0.710, which suggesting that the stock is 28.968% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Medtronic Plc has a quarterly dividend of $0.71 per share corresponding to a yield of 2.77%. Stryker Corp. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.84 per share. Medtronic Plc pays 77.47% of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic Plc quarterly revenues are $9B, which are larger than Stryker Corp. quarterly revenues of $6.1B. Medtronic Plc's net income of $1.4B is higher than Stryker Corp.'s net income of $859M. Notably, Medtronic Plc's price-to-earnings ratio is 27.55x while Stryker Corp.'s PE ratio is 48.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic Plc is 3.78x versus 5.80x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.